Arutimol eye drops 0.25% 5 ml
Condition: New product
993 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Timolol
Release form
Drops
Composition
Timolol hydromaleate 3.42 mg, which corresponds to the content of timolol 2.5 mg. Auxiliary substances: benzalkonium chloride solution (50%), povidone K30, sodium dihydrogen phosphate dihydrate, sodium monohydrogen phosphate dodecahydrate, disodium edetate dihydrate, water d / and.
Pharmacological effect
Antiglaucoma drug, non-selective blocker of β1 and β2-adrenergic receptors. It does not have an internal sympathomimetic and membrane stabilizing activity. When applied topically, it reduces both normal and elevated intraocular pressure as an eye drop by reducing the formation of intraocular fluid. It does not affect the size of the pupil and accommodation. The effect of the drug appears 20 minutes after instillation into the conjunctival sac. The maximum reduction in intraocular pressure occurs after 1-2 hours and persists for 24 hours.
Pharmacokinetics
When applied topically, timolol quickly penetrates the cornea. After instillation of Cmax timolol eye drops in the aqueous humor of the anterior chamber of the eye is achieved in 1-2 hours 80% timolol, used as eye drops, enters the systemic circulation by absorption through the vessels of the conjunctiva, nasal mucosa and lacrimal tract. The removal of metabolites of timolol is carried out mainly by the kidneys. In newborns and young children, C max timolol in the blood plasma exceeds this indicator in the blood plasma of adults.
Indications
Increased intraocular pressure (ocular hypertension), open-angle glaucoma, secondary glaucoma (including aphakic), angle-closure glaucoma (in combination with myotics as an additional means to reduce IOP), congenital glaucoma (with insufficient effectiveness of other therapeutic interventions).
Contraindications
Bronchial asthma or other severe chronic obstructive respiratory diseases; sinus bradycardia; cardiogenic shock; AV block II or III; heart failure; dystrophic processes in the cornea; severe atrophic rhinitis; pregnancy; lactation period; children under 18 years of age; allergic reactions on the components of the drug. With caution should use the drug in patients with pulmonary insufficiency,severe cerebrovascular insufficiency, chronic heart failure, diabetes mellitus, hypoglycemia, thyrotoxicosis, myasthenia, Raynaud's syndrome, pheochromocytoma, as well as other beta-adrenergic blockers. In patients with diabetes mellitus who take insulin or oral hypoglycemic agents, they can not be treated with the same resources.
Use during pregnancy and lactation
The use of Arutimol during pregnancy and lactation (breastfeeding) is contraindicated.
Dosage and administration
At the beginning of therapy, 1 drop of 0.25% or 0.5% Arutimol eye drops is instilled into the conjunctival sac 2 times / day. When the intraocular pressure is normalized, the maintenance dose is 1 drop of 0.25% eye drops 1 time / day. Treatment with Arutymolum is usually carried out long time. A break or a dose change is carried out only as prescribed by the attending physician.
Side effects
Local reactions: On the part of the organ of vision: irritation, conjunctival hyperemia, skin of the eyelids, burning and itching in the eyes, tearing, photophobia, corneal epithelium, punctate keratopathy, corneal hypesthesia, diplopia, ptosis. When conducting fistulizing antiglaucoma operations, retinal detachment may develop in the postoperative period. Systemic reactions From the cardiovascular system: heart failure, bradycardia, bradyarrhythmia, reduction of blood pressure, collapse, AV-blockade, cardiac arrest, palpitations, and brain cerebral hypoperfusion, the brain, and the brain, and the brain, the brain, the brain, the brain, the brain, the brain, the brain, the brain, the brain, the brain, the brain, the brain, the brain, the brain, the brain, the brain, the brain, the brain, the brain, the brain, the brain, the brain, the brain, the brain, the brain, the brain, the brain, the brain, the brain, the brain, the brain, the brain, the brain, the brain, the brain, the brain, the brain, the brain, to the brain, to the brain, to the brain, to the brain, to the brain. blood circulation. On the part of the respiratory system: rhinitis, shortness of breath, bronchospasm, pulmonary insufficiency. On the side of the central nervous system and peripheral nervous system: headache, goal ovokruzhenie, weakness, depression, paresthesias. From the digestive system: nausea, diarrhea. Allergic reactions: urticaria. From the skin: eczema, alopecia. Other: violation of sexual functions.
Overdose
Symptoms: possible development of systemic effects characteristic of beta-blockers: dizziness, headache, arrhythmia, bradycardia, decreased blood pressure, heart failure, bronchospasm, nausea, vomiting. Treatment: immediately wash the eyes with water or 0.9% sodium chloride solution; if necessary, conduct symptomatic therapy.
Interaction with other drugs
The combined use of Arutimol with eye drops containing epinephrine can cause pupil dilation. The specific effect of the drug is a decrease in intraocular pressure increased while the eye drops containing epinephrine and pilocarpine are used simultaneously; two beta-blockers should not be instilled into the eyes. Reducing blood pressure and slowing heart rate can be potentiated when Arutymol is combined with calcium channel blockers, reserpine and beta-blockers. Simultaneous use with insulin or oral hypoglycemic drugs can lead to hypoglycemia. , therefore, it is necessary to remove the drug 48 hours before the planned surgical intervention using general anesthesia. This data may also apply to drugs on that were applied long before.
special instructions
The patient should be warned about the need to regularly visit the doctor to measure intraocular pressure and examination of the cornea, as well as in the event of adverse reactions. If the patient wears soft contact lenses, then he should not use the drug Arutimol, because A preservative may adsorb to soft contact lenses and adversely affect eye tissue. Immediately after instillation, a short-term decrease in clarity of vision is possible. Hard contact lenses should be removed before instillation of the drug and installed again after 15 minutes. Correction may be required when transferring patients for treatment with Arutimol. refraction after the effects caused by previously used miotics. In the case of the forthcoming surgical intervention using general anesthesia, It is necessary to cancel the drug in 48 hours. Impact on the ability to drive vehicles and control mechanisms. During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require high concentration of attention, psychomotor speed and good vision (within 30 minutes after dropping in the eye), because The drug can help reduce blood pressure, fatigue and dizziness.To an even greater extent, this occurs when the drug interacts with alcohol.